NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 Standalone Revenue Up 93.5% YoY to ₹304.22 Cr, PAT Surges 206% to ₹17.15 Cr
Valiant Organics reported strong YoY operational growth for Q2 FY27 (quarter ended September 30, 2026), with standalone revenue from operations jumping 93.5% YoY to ₹304.22 crore compared to ₹157.21 crore in Q2 FY26. Standalone net profit for the quarter rose 206% YoY to ₹17.15 crore versus ₹5.60 crore in the same period last year, although it dipped sequentially from ₹21.82 crore in Q1. For H1 FY27, standalone revenue reached ₹535.76 crore with a net profit of ₹38.97 crore compared to ₹13.17 crore in H1 FY26. Cash flow from operations stood positive at ₹15.87 crore for H1, while capex spent on fixed assets and CWIP was ₹25.29 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுValiant Organics reported sharp YoY top-line and bottom-line expansion for Q2 and H1 FY27, backed by operational recovery and contribution from its Pharma segment.
ஏன் இது முக்கியம்The numbers confirm sustained turnaround momentum following subdued FY24-FY25 profitability, reflecting stronger volume off-take and improved realization spreads in its specialty chemicals and pharma businesses.
Q2 Revenue from Operations: ₹30,421.76 லட்சம்Q2 Standalone Net Profit: ₹1,715.05 லட்சம்H1 Revenue from Operations: ₹53,575.61 லட்சம்H1 Capex Spend: ₹2,528.89 லட்சம்Q2 Basic EPS: ₹6.12
📅 குறுகிய காலம்Market sentiment should react positively to the 93% YoY revenue jump and multi-fold profit surge, although the sequential moderation in PAT from Q1 (₹21.82 Cr to ₹17.15 Cr) will be noted.
📈 நீண்ட காலம்Validation of the diversification into Pharma alongside core Specialty Chemicals could provide structural margin stability and re-rate return ratios if sustained over coming fiscal years.
⚠ அபாய எச்சரிக்கைகள்
Working capital stretch indicated by a ₹79.61 Cr increase in trade receivables during H1 FY27
Sequential dip in quarterly net margin and profit (PAT down 21.4% QoQ)
👀 கவனிக்க வேண்டியவை
Track whether high quarterly revenue levels (~₹300 Cr) can be sustained in upcoming quarters and monitor operating cash flow conversion given a ₹79.61 Cr working capital drag in receivables.
Q1-FY27 Presentation: EBITDA Jumps 67.7% YoY to ₹416 Cr with Margin at 17.97%
Valiant Organics released its Q1-FY27 earnings presentation, highlighting strong operational recovery with revenue growing 13.3% YoY to ₹231.5 Cr (INR 2,315 Mn). Operating EBITDA surged 67.7% YoY to ₹41.6 Cr as EBITDA margin expanded by 584 bps to 17.97%, driven by a 410 bps drop in raw material costs as a percentage of sales. Consolidated PAT rose sharply to ₹29.3 Cr from ₹8.2 Cr in Q1-FY26, supported by higher operating leverage and an increased share of profit from associates.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company issued its Q1-FY27 investor presentation detailing quarterly chemistry-wise operational performance and margin expansion.
ஏன் இது முக்கியம்Demonstrates clear profitability recovery from the H1-FY26 trough, driven by lower input costs and better operating leverage across its hydrogenation and chlorination segments.
📅 குறுகிய காலம்Positive sentiment likely given the notable margin expansion to 17.97% and quarterly PAT rebound.
📈 நீண்ட காலம்The company's position as a leading domestic manufacturer of chlorophenol derivatives and benzene-based intermediates offers operating leverage as end-user demand normalizes.
⚠ அபாய எச்சரிக்கைகள்
End-user industry demand cyclicality in Dyes, Pigments, and Agrochemicals
Volatility in raw material prices impacting gross margin sustainability
👀 கவனிக்க வேண்டியவை
Track the sustainability of operating margins above 15% in subsequent quarters and volume recovery in key user industries like dyes, pigments, and agrochemicals.
Valiant Organics Q1 PAT Jumps 188% YoY to ₹21.82 Cr; MD Re-appointed for 3 Years
Valiant Organics reported a strong start to FY27 with standalone revenue growing 13.3% YoY to ₹231.54 Cr. Net profit surged 188% YoY to ₹21.82 Cr, significantly exceeding the quarterly average of the previous year. A key driver was the Pharma division, which turned around from a loss of ₹0.21 Cr to a profit of ₹16.85 Cr at the segment level. The board also ensured leadership continuity by re-appointing MD Sathiababu K. Kallada for a three-year term starting May 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported a significant recovery in profitability and segment performance for Q1 FY27, alongside securing leadership for the next three years.
ஏன் இது முக்கியம்The sharp jump in PAT and the turnaround in the Pharma segment suggest improved cost absorption and potentially better product pricing, addressing previous concerns about tepid demand in end-user industries.
Standalone Revenue (Q1 FY27): ₹231.54 கோடிStandalone PAT (Q1 FY27): ₹21.82 கோடிPharma Segment Result (Q1 FY27): ₹16.85 கோடிQ1 வருவாய் vs TTM வருவாய்: 31.3%MD Re-appointment Term: 3 Years
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the substantial earnings beat and the turnaround in the Pharma segment.
📈 நீண்ட காலம்If the company maintains this margin profile (EBITDA recovery noted in context), it could lead to a re-rating, especially if the Pharma division continues to contribute meaningfully to the bottom line.
⚠ அபாய எச்சரிக்கைகள்
High debt of ₹219 Cr relative to annual PAT
Sensitivity to demand in Pharma and Agro-chemical sectors
👀 கவனிக்க வேண்டியவை
Investors should monitor if the Pharma segment's sudden profitability is sustainable or driven by one-off orders. Watch for the upcoming AGM for shareholder approval of the MD's re-appointment and the registered office relocation to Tarapur.
Valiant Organics reported a strong performance for Q1 FY27, with consolidated revenue reaching ₹231.54 crore, a 13.3% increase from ₹204.41 crore in the same quarter last year. Consolidated net profit surged by 257% YoY to ₹29.26 crore, driven by a significant turnaround in the Pharma division which posted segment results of ₹16.85 crore compared to a loss of ₹0.21 crore YoY. The board also approved the re-appointment of Managing Director Sathiababu K. Kallada for a three-year term starting May 2027 and the relocation of the registered office to Tarapur, Palghar.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated a significant recovery in profitability and confirmed leadership continuity for the next three years while consolidating administrative operations.
ஏன் இது முக்கியம்The 257% YoY profit growth indicates a strong recovery from previous tepid demand cycles in the chemical and pharma sectors, significantly improving the company's earnings profile relative to its ₹868 Cr market cap.
📅 குறுகிய காலம்The stock is likely to react positively to the substantial earnings beat and the turnaround in the Pharma division's profitability.
📈 நீண்ட காலம்Leadership stability and the recovery of margins toward the 12% threshold are structural positives for long-term valuation re-rating.
⚠ அபாய எச்சரிக்கைகள்
Shareholder approval pending for MD re-appointment
Volatility in raw material spreads
Dependence on demand from the cyclical Agro-chemical sector
👀 கவனிக்க வேண்டியவை
Investors should monitor if the sharp margin recovery in the Pharma segment is sustainable over the coming quarters and watch for shareholder approval of the MD's re-appointment at the upcoming AGM.
Valiant Organics: CRISIL Revises Outlook to 'Stable' from 'Negative'; Reaffirms 'A-' Rating
CRISIL has revised the outlook on Valiant Organics' Rs 370 crore bank facilities to 'Stable' from 'Negative', while reaffirming the 'CRISIL A-' rating. This revision follows a significant operational turnaround in FY26, where the company reported a PAT of Rs 33.23 crore compared to a loss of Rs 3.43 crore in FY25. Operating margins improved to 12.75% in FY26 from 7.38% in FY25, driven by capacity ramp-up and steady demand. The financial risk profile remains healthy with a low gearing of 0.34x and improved interest coverage of 5.23x.
உச்சம் நம்பிக்கை
என்ன மாறியதுCRISIL revised the credit outlook from 'Negative' to 'Stable', reflecting improved business risk and profitability.
ஏன் இது முக்கியம்The outlook revision validates the company's operational recovery and reduces the risk of a credit downgrade, which can lead to better borrowing terms and improved investor confidence.
Total Bank Facilities Rated: Rs 370 CroreFY26 Operating Margin: 12.75%FY26 PAT: Rs 33.23 CroreGearing Ratio (Mar 2026): 0.34 timeவட்டி கவரேஜ்: 5.23 timesGross Current Assets (GCA): 177 நாட்கள்
📅 குறுகிய காலம்The outlook upgrade is likely to be viewed positively by the market in the coming days as it confirms the company's exit from a period of constrained profitability.
📈 நீண்ட காலம்The company's focus on diverse product portfolios in Pharma and Agro-chemicals, combined with logistical advantages, supports a steady 8-10% revenue growth target over the medium term.
⚠ அபாய எச்சரிக்கைகள்
Large working capital requirement (177 days GCA)
Vulnerability to raw material price volatility
High import dependence
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to sustain operating margins above the 13% threshold, which CRISIL identifies as a trigger for a potential rating upgrade. Additionally, watch for any reduction in the working capital cycle, which remains high at 177 days.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Valiant Organics Cancels Postal Ballot for Cessation of Partnership in Dhanvallabh Ventures LLP
Valiant Organics Limited has decided to halt its withdrawal as a partner from Dhanvallabh Ventures LLP. Following a board meeting on June 18, 2026, the company also cancelled a material related party transaction associated with this move. Consequently, the ongoing postal ballot process and the electronic voting event (EVEN - 139390) have been withdrawn with immediate effect. The board plans to deliberate further on the matter before making a final decision.
முக்கிய அம்சங்கள்
Board decided not to proceed with cessation as a partner of Dhanvallabh Ventures LLP for the time being.Related material related party transaction (RPT) has been put on hold following Audit Committee recommendations.Postal ballot process and electronic voting (EVEN - 139390) stand cancelled with immediate effect.The decision was based on management evaluation and submissions made during the June 18, 2026, board meeting.
👀 கவனிக்க வேண்டியவை
Investors should monitor future announcements for the rationale behind halting this transaction and its impact on the company's corporate structure. No immediate action is required as the status quo remains for the partnership.
Valiant Organics FY26 PAT Surges to ₹332 Mn; EBITDA Margins Expand to 11.94%
Valiant Organics reported a significant turnaround in FY26, with consolidated revenue growing 2.8% YoY to ₹7,388 million. The company achieved a Profit After Tax (PAT) of ₹332 million, recovering from a loss of ₹34 million in the previous fiscal year. EBITDA saw robust growth of 64.2% YoY to ₹882 million, driven by structural cost optimization and improved operational execution. The company's EBITDA margins expanded significantly by 447 basis points to reach 11.94% for the full year, supported by a strong Q4 performance.
முக்கிய அம்சங்கள்
FY26 Revenue increased to ₹7,388 Mn with a 64.2% YoY surge in EBITDA to ₹882 Mn.EBITDA margins expanded by 447 bps YoY to 11.94% due to raw material optimization and tighter overhead control.The company turned profitable with a PAT of ₹332 Mn in FY26 compared to a loss of ₹34 Mn in FY25.Hydrogenation remains the largest chemistry segment, contributing 48% of FY26 revenue.Q4 FY26 performance was strong with revenue of ₹2,178 Mn and an improved PAT margin of 7.21%.
👀 கவனிக்க வேண்டியவை
Investors should note the strong operational turnaround and margin recovery, which suggests improved efficiency and successful cost management. The stock may see positive momentum if the company sustains this profitability trend in the specialty chemicals sector.
Valiant Organics to Exit Dhanvallabh Ventures LLP; To Acquire 34.26% Stake in Valiant Laboratories
Valiant Organics Limited is seeking shareholder approval to cease its 73.15% partnership interest in its material subsidiary, Dhanvallabh Ventures LLP (DVLLP). As part of the settlement, the company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited (VLL), which represents approximately 34.26% of VLL's equity capital. Additionally, Valiant Organics will pay Rs. 6.34 crore to DVLLP to adjust its proportionate capital contribution. This restructuring effectively converts an indirect holding into a direct equity stake in Valiant Laboratories.
முக்கிய அம்சங்கள்
Cessation of 73.15% partnership interest in material subsidiary Dhanvallabh Ventures LLPAcquisition of 1,86,07,531 equity shares of Valiant Laboratories Limited (34.26% stake)Payment of Rs. 6,34,34,544 by Valiant Organics to DVLLP for capital adjustmentTransaction to be settled via inter-se off-market transfer based on fair market valueE-voting period for shareholders concludes on June 21, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the valuation of Valiant Laboratories Limited shares relative to the cash outflow to ensure the swap is value-accretive. The move simplifies the corporate structure by moving from an LLP partnership to direct equity ownership.
Valiant Organics to Receive 1.86 Cr Valiant Lab Shares in LLP Exit Settlement
Valiant Organics Limited has issued a corrigendum regarding its exit as a partner from Dhanvallabh Ventures LLP (DVLLP). As part of the settlement for its capital and profits, the company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited. Simultaneously, Valiant Organics will pay Rs. 6.34 crore to DVLLP to adjust its proportionate capital contribution. This material related party transaction is expected to conclude within 60 days of obtaining shareholder approval.
முக்கிய அம்சங்கள்
Cessation of partnership in Dhanvallabh Ventures LLP (DVLLP) approved by the Board.Settlement includes the transfer of 1,86,07,531 equity shares of Valiant Laboratories Limited to the company.Valiant Organics to pay Rs. 6,34,34,544 (inclusive of taxes) to DVLLP for capital adjustments.Transaction is based on fair market value and conducted on an arm's length basis.Expected completion within 60 days of receiving necessary shareholder and regulatory approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the market value of Valiant Laboratories Limited shares as they will now be a direct asset for Valiant Organics. Assess the impact of the Rs. 6.34 crore cash outflow against the liquidity and value of the shares received.
Valiant Organics to Exit Subsidiary DVLLP; to Receive 1.86 Cr Shares of Valiant Laboratories
Valiant Organics' board has approved the cessation of the company as a partner in Dhanvallabh Ventures LLP (DVLLP), which will consequently cease to be a subsidiary. To settle the company's capital and profit share, DVLLP will transfer 1,86,07,531 equity shares of Valiant Laboratories Limited to Valiant Organics. While DVLLP contributed 11.34% (₹83.79 Crores) to the consolidated net worth in FY26, its revenue contribution was negligible at 0.05% (₹0.37 Crores). The transaction is a material related party transaction and requires shareholder approval via a special resolution.
முக்கிய அம்சங்கள்
Valiant Organics to exit Dhanvallabh Ventures LLP (DVLLP), ending its status as a subsidiary.Settlement involves receiving 1,86,07,531 equity shares of Valiant Laboratories Limited from DVLLP.DVLLP contributed ₹83.79 Crores (11.34%) to consolidated net worth but only ₹0.37 Crores (0.05%) to revenue in FY26.The transaction is based on a valuation report by GBCA & Associates LLP and is conducted at arm's length.Completion is expected within 60 days of receiving shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the market value of Valiant Laboratories shares as they will now be held directly on the balance sheet. This restructuring simplifies the corporate structure without impacting core operating revenue.
Valiant Organics Board Approves Evaluation of Corporate Restructuring Options
Valiant Organics' Board has granted in-principle approval to explore various restructuring options, including potential mergers, demergers, or reorganizations involving its subsidiaries and associates. The primary goal is to simplify the complex holding structure and achieve operational and strategic synergies across its business units. This move is intended to unlock long-term value for shareholders and create more focused business platforms. While the evaluation process has begun, the company has not yet committed to a specific transaction or timeline.
முக்கிய அம்சங்கள்
Board granted in-principle approval on May 16, 2026, to evaluate restructuring options including mergers and demergers.The initiative aims to simplify the existing holding structure and achieve organizational synergies across its 6 manufacturing units.Potential outcomes include unlocking long-term shareholder value and creating strategically aligned business platforms.The Board will be apprised of the evaluation outcomes before determining the final course of action.
👀 கவனிக்க வேண்டியவை
Investors should monitor for specific details on the restructuring plan, as a demerger of specific business lines could provide a valuation re-rating. No immediate action is required until the definitive terms and ratios are announced.
Valiant Organics Q4 Net Profit Jumps 282% to ₹15.1 Cr; FY26 Turnaround to ₹34.4 Cr Profit
Valiant Organics reported a significant turnaround in FY26, posting a standalone net profit of ₹34.36 crore compared to a loss of ₹3.0 crore in FY25. Revenue for the full year grew marginally to ₹738.38 crore, while Q4 FY26 revenue rose 6.8% YoY to ₹217.70 crore. The bottom line was bolstered by a sharp 282% YoY increase in Q4 profit and a reduction in annual finance costs from ₹24.05 crore to ₹18.20 crore. Strategically, the company has also identified 'Pharma Business' as a new reportable segment, signaling a diversification beyond specialty chemicals.
முக்கிய அம்சங்கள்
Standalone Net Profit for FY26 reached ₹34.36 Cr, a sharp recovery from a loss of ₹3.0 Cr in FY25.Q4 FY26 Revenue from Operations increased to ₹217.70 Cr, up 6.8% from ₹203.81 Cr in the same quarter last year.Finance costs for the full year were reduced by 24.3%, falling to ₹18.20 Cr from ₹24.05 Cr.The Board approved the identification of 'Pharma Business' as a new reportable segment alongside Specialty Chemicals.Exceptional gain of ₹5.72 Cr recorded during the year contributed to the overall profitability improvement.
👀 கவனிக்க வேண்டியவை
The company's return to profitability and successful debt/finance cost management are strong positive indicators. Investors should watch for the growth trajectory and margin profile of the newly classified Pharma segment in upcoming quarters.
Valiant Organics Q3 FY26: 9M EBITDA Jumps 84% YoY to ₹616 Mn; PAT Turns Positive
Valiant Organics reported a strong turnaround for the 9-month period ending December 2025, with PAT reaching ₹175 Mn compared to a loss of ₹76 Mn in the previous year. While Q3 revenue faced a 14.8% YoY decline to ₹1,593 Mn due to pricing pressures and demand softness, the company's 9M EBITDA margin expanded significantly by 533 bps to 11.82%. Gross profit margins improved to 43%, reflecting better cost efficiencies and pricing discipline. The results were also supported by an exceptional insurance claim of ₹57 Mn.
முக்கிய அம்சங்கள்
9M-FY26 EBITDA surged 84.4% YoY to ₹616 Mn with margins expanding to 11.82%Turnaround in profitability with 9M PAT at ₹175 Mn vs a loss of ₹76 Mn in 9M-FY25Gross profit margin expanded by over 500 bps to 43% in 9M-FY26Q3-FY26 revenue declined 14.8% YoY to ₹1,593 Mn due to pricing and demand headwindsExceptional income of ₹57 Mn from an insurance claim boosted the bottom line
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin recovery and the company's ability to turn profitable despite industry-wide pricing pressures. Monitor the stabilization of the Chlorination and Hydrogenation segments for sustained growth.
Valiant Organics Q3 FY26 Net Profit Rises 30.5% YoY to ₹6.06 Cr; Exceptional Gain of ₹5.72 Cr
Valiant Organics reported a standalone net profit of ₹6.06 crore for the quarter ended December 31, 2025, marking a 30.5% increase from ₹4.65 crore in the previous year's corresponding quarter. While revenue from operations declined 14.8% year-on-year to ₹159.07 crore, the company showed sequential stability. Profitability was significantly aided by an exceptional gain of ₹5.72 crore from a fire insurance claim settlement. Notably, the company has achieved a turnaround for the nine-month period, posting a profit of ₹19.24 crore compared to a loss of ₹6.95 crore in the prior year period.
முக்கிய அம்சங்கள்
Standalone Net Profit increased to ₹6.06 crore in Q3 FY26 from ₹4.65 crore in Q3 FY25.Revenue from operations stood at ₹159.07 crore, a slight sequential increase from ₹157.21 crore in Q2 FY26.Recognized an exceptional gain of ₹5.72 crore relating to a fire insurance claim settlement for the Sarigam Division.Finance costs decreased significantly to ₹4.56 crore compared to ₹5.83 crore in the same quarter last year.9-month FY26 standalone profit reached ₹19.24 crore, reversing a net loss of ₹6.95 crore in 9M FY25.
👀 கவனிக்க வேண்டியவை
Investors should note the company's successful turnaround into profitability and the reduction in finance costs, which indicates better debt management. Monitor the execution of the new manufacturing agreement with Aarti Pharmalabs for potential long-term revenue growth.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
